Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.38 |
| ▸ | IL1B | P01584 | 6/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 4/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | PTGFR | P43088 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776591 | 0.94 | P2RX7 (0.40) | P2RX7IL1BCNR2CNR1 | |
| SCHEMBL22777090 | 0.92 | PDE4A (0.37) | P2RX7IL1BCNR2CNR1PDE4A | |
| SCHEMBL22791491 | 0.85 | P2RX7 (0.37) | P2RX7IL1BCNR2CNR1PDE4A | |
| SCHEMBL22776459 | 0.84 | P2RX7 (0.37) | P2RX7IL1BCNR2CNR1TBXA2R | |
| SCHEMBL22776453 | 0.84 | PTGER4 (0.34) | CNR2CNR1OPRL1PTGER4 | |
| SCHEMBL29614495 | 0.81 | CNR2 (0.34) | P2RX7IL1BCNR2CNR1PDE4A | |
| SCHEMBL22777091 | 0.81 | CNR2 (0.34) | P2RX7IL1BCNR2CNR1PDE4A | |
| SCHEMBL22776532 | 0.80 | NR4A2 (0.50) | P2RX7IL1BPDE4APDE4BPDE4C | |
| SCHEMBL29527053 | 0.80 | NR4A2 (0.50) | P2RX7IL1BPDE4APDE4BPDE4C | |
| SCHEMBL22777101 | 0.80 | HTR4 (0.36) | OPRL1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | PTGER4, PTGER1, PTGER2 | P2RX7 176/4885IL1B 3828/4885CNR2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.